5 Jan 2018 17:06
5 January 2018
Diurnal Group plc
("Diurnal" or the "Company")
Issue of Equity
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that further to the Director Dealings announcement released earlier today, it has applied to AIM for the admission of those 10,791 new ordinary shares of £0.05 each in the Company ("Shares"), which is anticipated to occur at 8.00am on 11 January 2018.
The Company notes that on 9 November 2017, only 109,293 new Shares were issued under the Diurnal Group plc Long Term Incentive Plan (rather than 109,296, as previously stated). Following admission of the new Shares, the Company's total issued share capital will therefore be 52,580,634 Ordinary Shares. Therefore, the total number of voting rights in the Company is 52,580,634. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Numis Securities Ltd (Nominated Adviser) | +44 (0)20 7260 1000 |
Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield | |
Corporate Broking: James Black | |
Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley | |
Corporate Broking: Tom Salvesen | |
FTI Consulting | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk